Skip to content

Study · Not a test of the peptide alone · 2001

1 result

[Clinical and immunological characteristics and specific features of the treatment of patients with recurrent sarcoidosis of respiratory organs].

Kostina ZI, Brazhenko NA, Gerasimova EV, Alekseev DIu, Kol'nikova OV, Balashova NM, Nasorina RN

Problemy tuberkuleza1 Jan 2001

PMID11508232 (opens in a new tab)PepBankPUB-11508232
Publisher pageAsk about this study
Jump to 1 result

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study1

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone1

In this study, Thymalin was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Thymalin.

  1. 01HumanNot a test of Thymalin aloneObservational studyEfficacy outcome

    In recurrent respiratory sarcoidosis, adaptogens including thymaline reportedly improved adaptive responses, treatment efficiency and prognosis, and reduced treatment duration.

    In plain wordsIn recurrent respiratory sarcoidosis, adaptogens including thymaline reportedly improved adaptive responses, treatment efficiency and prognosis, and shortened treatment.

    Peptide
    Thymalin
    Outcome
    IncreaseGeneral treatment response
    Study

    n: not reported in source

    Outcome group
    Overall treatment effect · Immune and inflammation

    Source sentences

    Summary
    To optimize treatment, the patients were given adaptogens (thymaline, levamisole, dibasole, etc.) that make AR better, by enhancing the efficiency of treatment, reducing its duration, and improving prognosis.
    1 context sentence
    Summary · context
    In chronic recurrent SRO, poor AR as stress and superactivation amount to as much as 86.1%.

    In this study, Thymalin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymalin.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    14 Oct 2026, 05:02 UTC

    Study results updated

  2. Version 1

    14 Oct 2026, 01:46 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.